{"id":56830,"date":"2019-06-12T20:30:46","date_gmt":"2019-06-13T00:30:46","guid":{"rendered":"http:\/\/www.imperialcrs.com\/blog\/?p=56830"},"modified":"2023-12-09T11:41:01","modified_gmt":"2023-12-09T11:41:01","slug":"bridging-the-gaps-in-study-conduct","status":"publish","type":"post","link":"https:\/\/www.imperialcrs.com\/blog\/events\/bridging-the-gaps-in-study-conduct\/","title":{"rendered":"Bridging the Gaps in Study Conduct"},"content":{"rendered":"\r\n

Today\u2019s Challenges<\/strong><\/p>\r\n\r\n\r\n\r\n

There are some amazing things happening in the field of clinical research right now. The hottest topics at the conferences I\u2019ve attended over the past 18 months have been those focused on disruptive innovations. All of the data points to trials becoming increasingly complex; from the number of procedures, to the geographic footprint, to the burden of proof required. We have all seen it.<\/p>\r\n\r\n\r\n\r\n

The number of trials in rare and orphan indications, as well as oncology, including rare types of cancer \u2013 has exploded. These are challenging studies and innovative companies are emerging to help meet that demand. Big data, virtual trials, risk-based monitoring, the use of artificial intelligence, etc. — it\u2019s all very exciting. It\u2019s also a very small, arguably tiny fraction of all trials taking place. In most of the terrific stories you hear, such advancements don\u2019t reflect critical mass. And, clinical operations teams often face big hurdles internally when introducing change. The future is bright, but the present is very challenging. Let\u2019s talk about how Imperial is helping firms like yours address the most common and disruptive challenges.<\/p>\r\n\r\n\r\n\r\n

Industry metrics communicate clear trends where there are still issues with various critical elements of study conduct. The time required to take new compounds from the bench to the bedside is taking longer than ever.<\/p>\r\n\r\n\r\n\r\n

Reports on trends in study conduct activities across the industry have almost become predictable. Time and again, the survey findings that fuel these reports point to things like regulatory challenges, delays in contracting, delays in site initiation, delays in enrollment, attrition problems, and supply chain issues. The same culprits, again and again!<\/p>\r\n\r\n\r\n\r\n

Our business development teams and operations teams here at Imperial are regularly meeting with clinical operations teams at sponsors and CROs across North America and Europe. Without a doubt, the issues we hear that clinical teams are challenged by the most include:<\/p>\r\n\r\n\r\n\r\n